Figure 6.

Dual treatment with isiPI3K and AEW541 arrested tumor growth in mice. UM-SCC47 and PDX ^HPV+ were injected or implanted subcutaneously (s.c.) into NSG mice. After tumors developed (tumor volume ~100 mm³), mice were randomized into 4 groups (tumors n = 8–12) and treated daily with the treatment indicated below. (A) Growth kinetics of UM-SCC47 tumors following treatment via oral gavage with vehicle, GDC0032 (10 mg/kg), AEW541 (30 mg/kg) or a combination of the two drugs. (B) Waterfall plot showing the change in the volume of UM-SCC47 tumors on endpoint day (15 days after starting the treatment) compared to the baseline for all treatment groups. (C) Tumor weight and images of UM-SCC47 CDX on endpoint day (15 days after starting the treatment). (D) Tumor growth kinetics of PDX ^HPV+ following treatment via oral gavage with vehicle, BYL719 (25 mg/kg), AEW541 (30 mg/kg), or a combination of the two drugs. Tumor growth was monitored using a caliper every 3 days. (E) Waterfall plot showing the change in tumor volume on the endpoint day (15–20 days after starting the treatment) compared to the baseline for all treatment groups. (F) Tumor weight and images of PDX ^HPV+ on the endpoint day (15–20 days after starting the treatment). Tumor volumes were normalized to initial volumes and presented as averaged percentages of the initial volumes ± SEM. Statistical significance was calculated using a two-way ANOVA. * p < 0.05; *** p < 0.001; **** p < 0.0001.